Chaudhuri, K. Ray
Odin, Per
Ferreira, Joaquim J.
Antonini, Angelo
Rascol, Olivier
Kurtis, Mónica M.
Storch, Alexander
Bannister, Kirsty
Soares-da-Silva, Patrício
Costa, Raquel
Magalhães, Diogo
Rocha, José Francisco
Funding for this research was provided by:
bial
Article History
Received: 8 July 2021
Accepted: 23 February 2022
First Online: 12 March 2022
Declarations
:
: The protocol was submitted to national Independent Ethics Committees and Competent Authorities and unconditional approval/favourable opinion must be obtained before the start of the study. All patients must provide written informed consent in order to participate in the study. The study was submitted to and approved by the following Independent Ethics Committees: in Spain, CEIm Hospital Clínic de Barcelona to cover all sites; in Portugal, Comissão de Ética para a Investigação Clínica to cover all sites; in the UK, London-Hampstead Research Ethics Committee and the Health Research Authority to cover all sites; in Germany, Ethikkommission bei der Medizinischen Fakultät der LMU München, Ethik-Kommission des Landes Berlin, Ethik-Kommission der Bayerischen Landesärztekammer, Ethikkommission der Fakultät für Medizin der Technischen Universität München, Ethikkommission der Landesärztekammer Thüringen, Universität Duisburg-Essen Ethik-Kommission and Ethik-Kommission bei der Landesärztekammer Hessen; in Italy, Comitato Etico per la Sperimentazione Clinica della Provincia di Padova, Comitato Etico per la sperimentazione clinica della provincia di Venezia e IRCCS San Camillo, Comitato Etico referente Area Pavia- Direzione Scientifica Comitato Etico ASL Brindisi, Comitato Etico Interaziendale Novara, Comitato Etico Indipendente locale - AOU Consorziale Policlinico di Bari and Comitato Etico di Brescia Comitato Etico per la Ricerca Biomedica delle Province di Chieti e Pescara e dell’Università degli Studi “G. D’Annunzio” di Chieti-Pescara.
: Not applicable.
: KRC has participated in advisory boards for AbbVie, UCB, GKC, Bial, Cynapsus, Lobsor, STADA, Medtronic, Zambon, Profile, Sunovion, Roche, Theravance, Scion, Britannia, Acadia, and 4D; has received honoraria for lectures from AbbVie, Britannia, UCB, Zambon, Novartis, Boehringer Ingelheim, Bial, Kyowa Kirin, and SK Pharma; has received investigator-initiated grants from Britannia, AbbVie, UCB, GKC, and Bial; and has received academic grants from the EU, IMI EU, Horizon 2020, Parkinson’s UK, National Institute for Health Research, Parkinson’s Disease Non Motor Group, Kirby Laing Foundation, NPF, Medical Research Council, and Wellcome Trust.PO has received honoraria for advice and lectures for AbbVie, Bial, Britannia, Lobsor, Nordic Infucare and Zambon, and has received grants from AbbVie.JJF has provided consultancy for Ipsen, GlaxoSmithKline, Novartis, Teva, Lundbeck, Solvay, Abbott, BIAL, Merck-Serono and Merz; and has received grants from GlaxoSmithKline, Grunenthal, Teva and Fundação MSD.AA has received compensation for consultancy and speaker-related activities from UCB, Boehringer Ingelheim, Britannia, AbbVie, Zambon, Bial, NeuroDerm, Theravance Biopharma, Roche; he receives research support from Chiesi Pharmaceuticals, Lundbeck, Horizon 2020 - Grant 825785, Horizon 2020 - Grant 101016902, Ministry of Education University and Research (MIUR) Grant ARS01_01081, Cariparo Foundation. He serves as consultant for Boehringer Ingelheim for legal cases on pathological gambling; owns Patent WO2015110261-A1; and owns shares in PD Neurotechnology Limited.OR has participated in advisory boards and/or provided consultancy for AbbVie, Adamas, Acorda, Addex, AlzProtect, ApoPharma, AstraZeneca, Axovant, Bial, Biogen, Britannia, Buckwang, CereSpir, Clevexel, Denali, INC Research, IPMDS, Lundbeck, Lupin, Merck, MundiPharma, NeurATRIS, NeuroDerm, Novartis, ONO Pharma, Osmotica, Parexel, Pfizer, Prexton Therapeutics, Quintiles, Roche, Sanofi, Servier, Sunovion, Theranexus, Takeda, Teva, UCB, Vectura, Watermark Research, XenoPort, XO, Zambon; received grants from Agence Nationale de la Recherche (ANR), CHU de Toulouse, France-Parkinson, INSERM-DHOS Recherche Clinique Translationnelle, MJFox Foundation, Programme Hospitalier de Recherche Clinique, European Commission (FP7, H2020), Cure Parkinson’s UK; and received a grant to participate in a symposium and contribute to the review of an article by the International Parkinson and Movement Disorder Society.MMK has received honoraria from AbbVie, Zambon, Bial and the International Parkinson and Movement Disorder Society.AS has received funding from the Deutsche Forschungsgemeinschaft (German Research Association) and the Helmholtz-Association, outside the submitted presented work. He has received honoraria for presentations/advisory boards/consultations from Desitin, Global Kinetics, Lobsor, STADA, Bial, RG Gesellschaft, and AbbVie, outside the submitted presented work. He has received royalties from Kohlhammer Verlag and Elsevier Press. He serves as an editorial board member of Stem Cells and Stem Cells International.KB has no competing interests.PSS is an employee of Bial – Portela & Cª, S.A.RC is an employee of Bial – Portela & Cª, S.A.DM is an employee of Bial – Portela & Cª, S.A.JFR is an employee of Bial – Portela & Cª, S.A.